company background image
IPDQ.F logo

ImpediMed OTCPK:IPDQ.F Stock Report

Last Price

US$0.04

Market Cap

US$69.2m

7D

12.6%

1Y

-32.8%

Updated

01 Feb, 2025

Data

Company Financials +

IPDQ.F Stock Overview

A medical technology company, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices in the Unites States and Europe. More details

IPDQ.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

ImpediMed Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for ImpediMed
Historical stock prices
Current Share PriceAU$0.04
52 Week HighAU$0.09
52 Week LowAU$0.02
Beta2.88
1 Month Change24.77%
3 Month Changen/a
1 Year Change-32.83%
3 Year Change-67.89%
5 Year Change-43.24%
Change since IPO-90.60%

Recent News & Updates

Recent updates

Shareholder Returns

IPDQ.FUS Medical EquipmentUS Market
7D12.6%-0.1%-0.9%
1Y-32.8%13.7%22.6%

Return vs Industry: IPDQ.F underperformed the US Medical Equipment industry which returned 13.7% over the past year.

Return vs Market: IPDQ.F underperformed the US Market which returned 22.6% over the past year.

Price Volatility

Is IPDQ.F's price volatile compared to industry and market?
IPDQ.F volatility
IPDQ.F Average Weekly Movementn/a
Medical Equipment Industry Average Movement8.8%
Market Average Movement6.4%
10% most volatile stocks in US Market18.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: IPDQ.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine IPDQ.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
199983Parmjot Bainswww.impedimed.com

ImpediMed Limited, a medical technology company, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices in the Unites States and Europe. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema and deliver snapshot of fluid status and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-car body composition analysis; and HF-Dex analysis for point-or care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications.

ImpediMed Limited Fundamentals Summary

How do ImpediMed's earnings and revenue compare to its market cap?
IPDQ.F fundamental statistics
Market capUS$69.19m
Earnings (TTM)-US$12.30m
Revenue (TTM)US$6.41m

10.8x

P/S Ratio

-5.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IPDQ.F income statement (TTM)
RevenueAU$10.32m
Cost of RevenueAU$1.31m
Gross ProfitAU$9.01m
Other ExpensesAU$28.80m
Earnings-AU$19.79m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0098
Gross Margin87.27%
Net Profit Margin-191.78%
Debt/Equity Ratio0%

How did IPDQ.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 19:35
End of Day Share Price 2025/01/29 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ImpediMed Limited is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dennis HulmeAPP Securities Pty Ltd.
Matthijs SmithCanaccord Genuity
Elyse ShapiroCanaccord Genuity